Copyright
©The Author(s) 2023.
World J Clin Oncol. Dec 24, 2023; 14(12): 606-619
Published online Dec 24, 2023. doi: 10.5306/wjco.v14.i12.606
Published online Dec 24, 2023. doi: 10.5306/wjco.v14.i12.606
Table 4 Adverse events in patients treated with high-dose methotrexate plus zanubrutinib
| Adverse event | Grade 1 | Grade 2 | Grade 3 | Grade 4 | Total (%) |
| Hematological toxicities | |||||
| Leukopenia | 3 | 7 | 1 | 11 (57.9) | |
| Neutropenia | 3 | 6 | 2 | 11 (57.9) | |
| Lymphocytopenia | 6 | 8 | 2 | 16 (84.2) | |
| Thrombocytopenia | 5 | 1 | 6 (31.6) | ||
| Anemia | 8 | 10 | 1 | 19 (100) | |
| Non-hematological toxicities | |||||
| Transaminase increase | 4 | 4 (21.1) | |||
| Creatinine increase | 2 | 1 | 3 (15.8) | ||
| Hypoalbuminemia | 16 | 2 | 18 (94.7) | ||
| Hypokalemia | 10 | 4 | 1 | 15 (78.9) | |
| Lung infection | NA | ||||
- Citation: Wang N, Chen FL, Pan L, Teng Y, Wei XJ, Guo HG, Jiang XM, Huang L, Liu SC, Liang ZL, Li WY. Clinical outcomes of newly diagnosed primary central nervous system lymphoma treated with zanubrutinib-based combination therapy. World J Clin Oncol 2023; 14(12): 606-619
- URL: https://www.wjgnet.com/2218-4333/full/v14/i12/606.htm
- DOI: https://dx.doi.org/10.5306/wjco.v14.i12.606